These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 17355999

  • 21. [Use of oral anticoagulants to prevent central venous catheter-related thrombosis in hemodialysis].
    Mandolfo S, Gallieni M.
    G Ital Nefrol; 2010; 27(5):490-7. PubMed ID: 20922680
    [Abstract] [Full Text] [Related]

  • 22. Catheter-related deep venous thrombosis and other catheter complications in children with cancer.
    Journeycake JM, Buchanan GR.
    J Clin Oncol; 2006 Oct 01; 24(28):4575-80. PubMed ID: 17008698
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Burris HA.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patients.
    Magagnoli M, Masci G, Castagna L, Zucali PA, Morenghi E, Pedicini V, Santoro A.
    Anticancer Res; 2005 Apr 01; 25(4):3143-7. PubMed ID: 16080578
    [Abstract] [Full Text] [Related]

  • 29. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2.
    Eastman ME, Khorsand M, Maki DG, Williams EC, Kim K, Sondel PM, Schiller JH, Albertini MR.
    Cancer; 2001 Feb 15; 91(4):806-14. PubMed ID: 11241250
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Trisodium citrate 4%--an alternative to heparin capping of haemodialysis catheters.
    Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM.
    Nephrol Dial Transplant; 2007 Feb 15; 22(2):477-83. PubMed ID: 17018541
    [Abstract] [Full Text] [Related]

  • 32. Anticoagulation for patients with cancer and central venous catheters.
    Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Sperati F, Cook D, Schünemann H.
    Cochrane Database Syst Rev; 2011 Apr 13; (4):CD006468. PubMed ID: 21491394
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Cancer-associated venous thrombosis in the surgical setting.
    Behranwala KA, Williamson RC.
    Ann Surg; 2009 Mar 13; 249(3):366-75. PubMed ID: 19247020
    [Abstract] [Full Text] [Related]

  • 37. Thromboembolic complications related to central venous access catheters in cancer patients.
    Freytes CO.
    Semin Thromb Hemost; 2007 Jun 13; 33(4):389-96. PubMed ID: 17525896
    [Abstract] [Full Text] [Related]

  • 38. Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital.
    Marinella MA, Kathula SK, Markert RJ.
    Heart Lung; 2000 Jun 13; 29(2):113-7. PubMed ID: 10739487
    [Abstract] [Full Text] [Related]

  • 39. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants.
    DeLoughery TG.
    Crit Care Clin; 2005 Jul 13; 21(3):497-512. PubMed ID: 15992670
    [Abstract] [Full Text] [Related]

  • 40. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study.
    Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, Gussoni G, Barbui T, Mannucci PM, CATHEM Study Group.
    Br J Haematol; 2005 Jun 13; 129(6):811-7. PubMed ID: 15953009
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.